-
Kuros Biosciences‘ MagnetOs Bone Graft Successfully Achieves Three Key Milestones
Completion of enrolment in PARTNER clinical trial, comparing MagnetOs to autograft First patient treated with MagnetOs Flex Matrix 10,000 patients now treated with MagnetOs worldwide Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs bone graft has successfully achieved three key clinical and commercial milestones, with completion of enrolment in the PARTNER clinical trial, the first patient treated with MagnetOs Flex Matrix and reaching a total of 10,000 patients treated with MagnetOs worldwide. Joost de Bruijn, Chief Executive Officer of Kuros, said: "The truly significant progress of MagnetOs is underlined by these three major milestones. The PARTNER trial marks an…
-
Kuros Biosciences reports results for the first six months of 2022
Financial highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022 Product sales increased by 58% to CHF 5.7 million Operational highlights FDA cleared MagnetOs Granules for use in expanded spinal indications FDA cleared MagnetOs Flex Matrix for spinal indications MagnetOs Easypack Putty launched in the US in May 2022 Favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial USD 5 million milestone recognized by Kuros, trigged by acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, reported a 58% increase in sales in…
-
Annual General Meeting of Kuros Biosciences approves all resolutions
. Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved all resolutions proposed by the Board of Directors. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2021 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and the persons entrusted with the Management, voted in favor of the proposed appropriation of the Annual Results and approved the compensation for the members of the Board of Directors and the Executive Committee. Clemens van Blitterswijk was re-elected as Chairman and Leanna Caron, Joost de Bruijn, Scott P. Bruder, Oliver Walker and Chris Fair…
-
Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial
Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized controlled trials for MagnetOs Data will support product approvals at hospitals and within hospital systems Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today promising preliminary results from the first of its five planned randomized controlled trials for its MagnetOs family, comparing MagnetOs Granules to the gold standard of autograft bone. Data from the prospective, multi-center, intra-patient-controlled trial showed a fusion rate for MagnetOs of 78%, compared to 42% for autograft. This compares favorably to fusion rates of 55-71% reported for other synthetic bone…
-
Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.
Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs product Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the commercial launch of MagnetOs Easypack Putty in the U.S., at the 22nd Annual Meeting of the International Society for the Advancement of Spine Surgery (ISASS), held in the Bahamas, June 1-4 2022. MagnetOs Easypack Putty is a soft and moldable formulation that is provided in an open-ended dispenser and is ready to use with no requirement for thawing or mixing with blood or bone marrow aspirate. The moldable and cohesive properties of MagnetOs…
-
Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
. Medical devices Q1 2022 sales accelerate, rising 102% over Q1 2021 FDA cleared MagnetOs Granules for expanded indications in spine and MagnetOs Flex Matrix as bone void filler in posterolateral spine Promising first-in-human data from Phase II trial of Fibrin-PTH (KUR-113) in tibial fractures Milestone payment of $5 million to be received from Checkmate Pharmaceuticals Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today provided a first-quarter business update, showing a significant acceleration in product sales of its Medical devices segment. Medical devices sales increased 102% in Q1 2022 compared to Q1 2021. The U.S. Food and Drug Administration (FDA) cleared MagnetOs Granules for expanded…
-
Kuros Biosciences’s MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
Clearance as a bone void filler for use in the posterolateral spine Third FDA clearance for MagnetOs in the last 7 months Product provides opportunity to de-risk U.S. commercialization plans Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs Flex Matrix has been cleared by the U.S. Food and Drug Administration (FDA) as a bone void filler for use in the posterolateral spine. MagnetOs Flex Matrix is a new open matrix bone graft with a unique fibrillar and flexible structure that optimizes the effect of Kuros‘ established pro-healing NeedleGripTM surface technology for more predictable fusion. U.S. spine surgeons routinely…
-
Kuros Biosciences’s MagnetOs Granules cleared by FDA for expanded spinal indications
Rare clearance for bone graft for standalone use in spine based on human clinical data Clearance attained with evidence from Level 1 randomized controlled trial Positions MagnetOs above most other 510(k)-cleared bone grafts on the market Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs Granules has been cleared by the U.S. Food and Drug Administration (FDA) for expanded indications in the spine, making it only the second-ever bone graft to achieve clearance for standalone use in the spine based on human clinical data. The FDA clearance was attained using radiographic data, clinical outcomes and safety data from 50 patients…
-
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
. Phase II data published in peer-reviewed Journal of Bone and Joint Surgery Healing rate at six months post-surgery was higher than standard of care Significantly de-risks development of Fibrin-PTH for spinal fusion Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the publication of first-in-human data from a Phase II trial of Fibrin-PTH (KUR-113) in open tibial shaft fractures in The Journal of Bone and Joint Surgery (JBJS), the leading peer-reviewed orthopedic research journal. The article, entitled “Novel Parathyroid Hormone-Based Bone Graft, KUR-113, in Treatment of Acute Open Tibial Shaft Fracture”, outlined results from the multicenter, randomized, controlled dose-finding study with 200…
-
Kuros Biosciences reports continued increase in MagnetOs U.S. sales
MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020 Kuros expanding MagnetOs range to increase perioperative solutions for surgeons Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update on its commercial activities. Direct sales of MagnetOs in the U.S. continued to accelerate in Q3 2021, with a year-to-date increase of 119% over the same period in 2020. Kuros recently showcased new products in the MagnetOs range, including a new 2.5cc unit that is ideal for filling gaps in the spine during posterior cervical fusion procedures, a new formulation of MagnetOs that includes a collagen carrier, and MagnetOs Easypack…
